Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
Want to see PHAT full AI Analyst Report?
PHAT Stock Chart & Stats
$13.19
-$0.22(-3.06%)
At close: 4:00 PM EST
$13.19
-$0.22(-3.06%)
Day’s Range― - ―
52-Week Range$2.21 - $18.31
Previous CloseN/A
Volume285.74K
Average Volume (3M)1.03M
Market Cap
$1.03B
Enterprise Value$843.99M
Total Cash (Recent Filing)$180.90M
Total Debt (Recent Filing)$2.63M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Aug 06, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.12
Shares Outstanding79,755,950
10 Day Avg. Volume971,402
30 Day Avg. Volume1,028,945
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-2.76
Price to Sales (P/S)6.91
P/FCF Ratio-7.25
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue4.12
Enterprise Value/Gross Profit4.85
Enterprise Value/Ebitda-8.79
Forecast
1Y Price Target
$24.25Price Target Upside83.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$332.05M
Bulls Say, Bears Say
Bulls Say
Commercialization MomentumStrong prescription growth and market data indicate accelerating adoption of VOQUEZNA among gastroenterology specialists, supporting upside to sales forecasts.
Financial FlexibilityDebt restructuring combined with an equity capital raise reduced interest burden and improved financial flexibility, reinforcing the company's path toward operating profitability.
Revenue Guidance And Analyst OutlookRevenue guidance above consensus and analyst model upgrades increased confidence in near-term sales momentum and led to more favorable analyst recommendations.
Bears Say
Execution Risk To ProfitabilityAchieving profitability hinges on sustaining sales growth while controlling operating costs, creating execution risk if either element underperforms.
Generic Competition RiskPotential entry of generic competitors could erode VOQUEZNA's market share and exert downward pressure on pricing and margins.
Sales Channel UncertaintyUncertainty about the need to broaden engagement with primary care physicians could complicate the commercial strategy and raise marketing and adoption costs.
Phathom Pharmaceuticals News
PHAT FAQ
What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $2.21 and its highest was $18.31 in the past 12 months.
What is Phathom Pharmaceuticals’s market cap?
Phathom Pharmaceuticals’s market cap is $1.03B.
When is Phathom Pharmaceuticals’s upcoming earnings report date?
Phathom Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 93 days.
How were Phathom Pharmaceuticals’s earnings last quarter?
Phathom Pharmaceuticals released its earnings results on Apr 30, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.08.
Is Phathom Pharmaceuticals overvalued?
According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued.
Does Phathom Pharmaceuticals pay dividends?
Phathom Pharmaceuticals does not currently pay dividends.
What is Phathom Pharmaceuticals’s EPS estimate?
Phathom Pharmaceuticals’s EPS estimate is -0.2.
How many shares outstanding does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 79,755,950 shares outstanding.
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Phathom Pharmaceuticals reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -4.924%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
Currently, no hedge funds are holding shares in PHAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phathom Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.25 (83.85% Upside)
$24.25 (83.85% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 216.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
227.29%
12-Months-Change
Fundamentals
Return on Equity
55.14%
Trailing 12-Months
Asset Growth
-31.35%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
PHAT Company Deck
PHAT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong commercial momentum and meaningful year-over-year growth, highlighted by rapid prescription uptake, high new-to-brand conversion among gastroenterologists, expanding sales coverage, an 80% gross margin, and ahead-of-schedule EoE enrollment. Management maintained guidance, reduced operating cash spend year-over-year, and ended the quarter with $181M in cash. Near-term challenges include Q1 being light versus internal expectations (seasonality and deployment timing), a modest sequential revenue increase (+1% vs Q4), an operating loss excluding stock-based compensation (~$9.9M), and persistent high gross-to-net discounts (55%–59% guidance) with variability due to channel mix. Competitive risk from a potential second P-CAB entrant in 2027 and a notable share of cash-pay prescriptions (~37% in Q1) remain considerations. On balance, the positives (robust growth, market share gains, commercial execution, clinical progress, and expense discipline) outweigh the near-term headwinds and uncertainties.View all PHAT earnings summariesPHAT Stock 12 Month Forecast
Average Price Target
$24.25
▲(83.85% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Urogen Pharma
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
8.78% Insiders
10.44% Mutual Funds
11.50% Other Institutional Investors
60.10% Public Companies and Individual Investors